Neuphoria Therapeutics Inc.
NEUP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001191070
No open-market purchases or sales by Neuphoria Therapeutics Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $8.71M in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Neuphoria Therapeutics Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- +3 vs. Q1 2026
- Shares held
- 1.99M
- +236.1K (+13.4%) vs. Q1 2026
- Total value
- $8.71M
- +$1.56M (+21.8%) vs. Q1 2026
- New holders
- 6
- 6 more added
- Sold out
- 3
- 2 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NEUP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 22 | $8.71M |
| Q1 2026 | 19 | $7.15M |
| Q4 2025 | 21 | $5.69M |
| Q3 2025 | 15 | $2.30M |
| Q2 2025 | 9 | $1.26M |
| Q1 2025 | 7 | $935.4K |
| Q4 2024 | 8 | $273.4K |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Neuphoria Therapeutics Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Caitong International Asset Management Co., Ltd | 3 | $13 | 0.00% | +3 | New |
| Morgan Stanley | 58 | $254 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 2,117 | $9.25K | 0.00% | −199−8.6% | Reduced |
| Merck & Co., Inc. | 10,027 | $43.8K | 0.01% | 00.0% | Unchanged |
| Northern Trust Corp | 10,610 | $46.4K | 0.00% | +10,610 | New |
| Commonwealth Equity Services, LLC | 11,222 | $49.0K | 0.00% | 00.0% | Unchanged |
| Boothbay Fund Management, LLC | 14,000 | $61.2K | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 14,903 | $65.1K | 0.00% | +14,903 | New |
| HRT Financial LP | 22,865 | $99.0K | 0.00% | +22,865 | New |
| XTX Topco Ltd | 23,089 | $100.9K | 0.00% | +23,089 | New |
| Renaissance Technologies LLC | 25,500 | $111.4K | 0.00% | +25,500 | New |
| FNY Investment Advisers, LLC | 26,500 | $115.0K | 0.04% | 00.0% | Unchanged |
| ADAR1 Capital Management, LLC | 30,000 | $131.1K | 0.01% | 00.0% | Unchanged |
| Vanguard Fiduciary Trust Co | 33,806 | $147.7K | 0.00% | +217+0.6% | Added |
| Ikarian Capital, LLC | 47,443 | $207.3K | 0.03% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 49,516 | $216.4K | 0.00% | −2,491−4.8% | Reduced |
| Citadel Advisors LLC | 72,559 | $317.1K | 0.00% | +53,228+275.4% | Added |
| Balyasny Asset Management LLC | 142,228 | $621.5K | 0.00% | +450.0% | Added |
| Shay Capital LLC | 155,822 | $680.9K | 0.08% | +4,812+3.2% | Added |
| Vanguard Capital Management LLC | 173,488 | $758.1K | 0.00% | +74,972+76.1% | Added |
| AdvisorShares Investments LLC | 252,909 | $1.11M | 0.13% | +97,542+62.8% | Added |
| Lynx1 Capital Management LP | 875,328 | $3.83M | 0.44% | 00.0% | Unchanged |
| Squadron Capital Management LLC | 0 | $0 | 0.00% | −76,728−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −12,033−100.0% | Sold out |
| Rhumbline Advisers | 0 | $0 | 0.00% | −202−100.0% | Sold out |